LAUSR

Treatment of multiple myeloma (MM) has changed dramatically over the last two decades and has led to a significant improvement in outcomes for patients of all ages. Triplet combinations are now widely accepted as standard induction therapies for transplant-eligible patients and are also emerging for relapsed/refractory disease, thus evoking considerable enthusiasm among the myeloma community. However, given the ultra-fast development of new treatment regimens, the treating physician will face new challenges in terms of risk-adapted use of these protocols, optimal sequencing and ultimately management of patients with multiclass refractory disease.